Awaiting development: Guidance and quality standards

Showing 61 to 70 of 295

Guidance and quality standards awaiting development
Title	Type
Deucravacitinib for treating active psoriatic arthritis TS ID 11981	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154	Technology appraisal guidance
Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain	Medical technologies guidance
Digital platforms to support cardiac rehabilitation	Medical technologies guidance
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457	Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]	Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046	Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]	Technology appraisal guidance
Dupilumab for treating bullous pemphigoid [ID6479]	Technology appraisal guidance